Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis.
Beatriz GrosHannah RossMaureen NwabuezeNathan Constantine-CookeLauranne A A P DerikxMathew LyonsClaire O'HareColin NobleIan D ArnottGareth-Rhys JonesCharlie W LeesNikolas PlevrisPublished in: Therapeutic advances in gastroenterology (2024)
VDZ effectiveness appears enduring with favourable long-term safety profile. VDZ persistence was influenced by previous exposure to biologics/small molecules, disease distribution and steroid use at baseline in our study.